Contributor: How Much? Addressing Medicines’ Cost and Value

Why It Matters

If pricing ignores comprehensive value, it risks under‑funding breakthrough therapies and limiting patient access, affecting the entire healthcare ecosystem.

Key Takeaways

• HTA often narrows value to limited clinical outcomes
• Narrow assessments can suppress drug prices, limiting future innovation
• HEMA report reinforces existing HTA methods, missing broader benefits
• Aligning price with comprehensive value improves patient access
• Balanced buyer‑seller dialogue essential for sustainable reimbursement

Pulse Analysis

Drug pricing remains a polarizing issue in the United States, where patients encounter medication costs at the pharmacy counter daily. While governments worldwide increasingly set price caps, the underlying methodology—health technology assessment—determines which benefits count toward a drug’s worth. Traditional HTA models prioritize direct clinical outcomes, overlooking indirect effects such as caregiver burden, workforce productivity, and long‑term societal gains. This narrow lens can lead to price suppression that discourages manufacturers from investing in high‑risk, high‑reward research, ultimately slowing the pipeline of innovative therapies.

The Health Economics Methods Advisory (HEMA) report, a collaborative effort by ICER, Canada’s Drug Agency, and England’s NICE, was expected to broaden the value conversation. Instead, its recommendations largely uphold the status quo, preserving a limited set of benefit criteria. By aligning closely with existing HTA frameworks, HEMA risks cementing a valuation approach that undervalues breakthrough treatments, especially in complex areas like neuro‑degenerative diseases. Critics argue that this could exacerbate access gaps, as lower price expectations may deter companies from launching novel products in markets with stringent reimbursement standards.

To reconcile price and value, stakeholders must adopt a more holistic assessment that captures the full spectrum of a drug’s impact—including caregiver costs, employer productivity, and quality‑of‑life improvements. Transparent, collaborative negotiations between payers and manufacturers can bridge the gap between buyer incentives for lower prices and seller goals for fair compensation. Such a balanced approach not only safeguards patient access today but also fuels the innovation pipeline needed for tomorrow’s cures, ensuring a sustainable pharmaceutical ecosystem.